guest ::
| Home > Publications database > Combined Photon and Carbon Ion Radiotherapy for Sinonasal Malignancies - Results of the HIT-SNT Prospective Phase II-Trial. |
| Home > Publications database > Combined Photon and Carbon Ion Radiotherapy for Sinonasal Malignancies - Results of the HIT-SNT Prospective Phase II-Trial. |
| Journal Article | DKFZ-2023-02146 |
; ; ; ; ; ; ; ; ; ; ; ;
2024
Elsevier Science
Amsterdam [u.a.]
This record in other databases: 
Please use a persistent id in citations: doi:10.1016/j.ijrobp.2023.09.037
Abstract: Radiation treatment of sinonasal malignancies is a challenging task due to proximity to critical structures of the head and neck and skull base. Local tumor control is highly dose-dependent, but dose application is limited due to accompanying toxicity and dose constraints. To evaluate the toxicity and efficacy of combined radiation treatment with IMRT and carbon ion boost, we conducted a prospective phase-II IMRT-HIT-SNT-trial (SNT = sinonasal tumors).Between 2011 and 2019 we treated 35 patients with histologically proven, incompletely resected or inoperable adeno- (51%) or squamous-cell-carcinoma (49%) of the paranasal sinuses with combined IMRT (50 Gy) and carbon ion boost (24 Gy(RBE)) to a total dose of 74 Gy.Acute mucositis CTCAE grade III occurred in 12% of patients (n=4) and was accompanied by odynophagia CTCAE grade III.. Except for one case of grade III weight loss, no other acute high-grade toxicity (grade III-IV) was observed. In a small patient cohort of 15 patients eligible for long-term follow-up we have seen no high-grade (≥grade III) long-term side effects 2 years after RT. None of these patients suffered from therapy-associated vision or hearing loss. Secondary endpoints were 2-year-OS, 2-year-LPFS, 2-year-PFS and 2-year-MFS with 79.4%, 61.8%, 61.8% and 64.8%, respectively.To our knowledge, this is the first prospective data on toxicity and outcome of bimodal radiation therapy for the rare entity of sinonasal malignancies. Our study shows a low rate of CTCAE-reported acute toxicity with reasonable tumor control and survival rates after bimodal radiation therapy, which therefore remains a therapy approach to be further evaluated.
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz
; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |